Sun et al. showed that systemic adipose tissue browning by β3-AR agonists suppresses tumor growth in hepatocellular carcinoma and pancreatic ductal adenocarcinoma models, highlighting the potential for anti-tumor immunity [8]. Here, ADRB3 is linked to pancreatic ductal adenocarcinoma.